Our Blog

In this very comprehensive video, Prof. Kenneth Cusi, USA, reviews the guidelines on NAFLD that are currently being updated. He also shares highlights on the rationale of PPARs in NASH and discusses the clinical trials with Pioglitazone. He addresses the positive results as well as the misconceptions and barriers for using PPAR-γ in NASH.

Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.

Discover the very special relationship between Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM) with Prof Kenneth Cusi, USA. Each of these conditions seems to worsen the other.

Giada Sebastiani et al. review the current status of knowledge regarding this emerging comorbidity in people with HIV.

Prof. Sacks, USA discusses the available data on the PPAR gamma agonist – Pioglitazone. His analysis is based on the PROACTIVE and IRIS (Ischemic Stroke or Transient Ischemic Attack) studies.

The aims of the analysis by Ali Canbay et al. were firstly, to evaluate the probability of all-cause mortality and determine the impact of liver disease severity, demographics and comorbidities on the risk of all-cause mortality and secondly, to evaluate the probability of liver disease progression in a large real-world cohort of NAFLD patients in Germany.

In this meta-analysis by A. Lin et al. based on data pooled from all 27 studies, the prevalence of NAFLD among Inflammatory Bowel Disease was 32% (95% CI, 24%-40%) with substantial heterogeneity (I2 = 98%).

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.

The goal of K. Cusi et al. was to review evidence about the complex association between NAFLD and T2DM, and highlight the potential for disease co-management with the available medications used for the treatment of diabetes.